Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

Proteome dynamics at broken replication forks reveal a distinct ATM-directed repair response suppressing DNA double-strand break ubiquitination

(2021) Kyosuke Nakamura et al.   MOLECULAR CELL

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study

(2020) Wassim Abida et al.   CLINICAL CANCER RESEARCH

Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.

(2020) Matthew Raymond Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic targeting of the DNA damage response in prostate cancer

(2020) Catherine H. Marshall et al.   CURRENT OPINION IN ONCOLOGY

Olaparib for Metastatic Castration-Resistant Prostate Cancer

(2020) Johann de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural basis for allosteric PARP-1 retention on DNA breaks

(2020) Levani Zandarashvili et al.   SCIENCE

612MO Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study

(2020) R. Lozano Mejorada et al.   ANNALS OF ONCOLOGY

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

(2020) Wassim Abida et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

(2020) Maha Hussain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors

(2020) Antje Neeb et al.   EUROPEAN UROLOGY

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer

(2019) Elena Castro et al.   JOURNAL OF CLINICAL ONCOLOGY

Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer

(2019) Isaac E. Kim et al.   BMC Urology

Tumour lineage shapes BRCA-mediated phenotypes

(2019) Philip Jonsson et al.   NATURE

Pan-cancer whole-genome analyses of metastatic solid tumours

(2019) Peter Priestley et al.   NATURE

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

(2019) Sara A. Hurvitz et al.   ONCOLOGIST

The long tail of oncogenic drivers in prostate cancer

(2018) Joshua Armenia et al.   NATURE GENETICS

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal

(2018) James X. Sun et al.   PLoS Computational Biology

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

(2018) Nicholas C. Turner et al.   CLINICAL CANCER RESEARCH

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

(2017) Johann de Bono et al.   Cancer Discovery

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

(2016) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH